即使到今天,全世界各地仍有許多為眼疾所苦的病患!我曾於哈佛大學眼科中心研究與學習,很高興的在近日,母校正式來函邀請我成為美國最專業、也是世界最頂尖的馬薩諸塞州醫院眼耳科研究醫學會的一員。在新的一年,我把這樣的榮譽分享給我們所有的好友們…

20100105_呂醫師哈佛大學邀請2.JPG 

Dear Colleague

It is with great pride that I reach out to keep you informed of significant developments within the department of ophthalmology at the Massachusetts Eye and Ear Infirmary and Harvard Medical School.

此函為正式邀請呂俊憲醫師(Paul C S Lu MD)成為馬薩諸塞州醫院及哈佛醫學院眼耳科醫學會裡重要一員。



We are pleased to announce that after nearly a decade of litigation, Mass. Eye and Ear and the Department of Ophthalmology have prevailed in their royalty case against QLT,Inc. This Summer, we received $126 million from QLT, Inc.as part of a judgment that awarded royalties of 3.01% on worldwide past, present and future net sales for Visudyne, the first approved drug treatment for age-related macular degeneration. Photodynamic therapy using Visudyne was developed here at Mass. Eye and Ear.

我們很高興地宣布,經過近十年的訴訟,馬薩諸塞州眼耳科對QLT公司的法律訴訟案件,確定勝訴。今年夏天,我們已收到來自QLT公司的一億二千六百萬美元,此一費用的3.01%獲准做為世界各地特許權的使用費,Visudyne從過去到現在的售額中,第一次要物批准做為治療老年性黃斑性病變的藥物。光動力療法利用Visudyne的資金,治療眼睛及耳朵的問題,並於馬薩諸塞州醫院開發研究。



As a result of this victory, substantial new funds will be available to Mass. Eye and Ear for academic programs. Research initiatives and advancements in patient care. Supporting talented faculty and staff is paramount to our success in all of these areas. We are now developing new initiatives to support faculty at the early and mid-stages of their careers and to enhance trainee support and recruitment. We hope also to fund several new professorships. Additionally, we will allocate funding toward important research programs in genetics and molecular biology of retinal disorders and glaucoma, including initiation gene therapy trials.

這一訴訟的成功,將可使大量新資金轉而提供給美國馬薩諸塞州眼耳科的學術課程,其中包括:初階研究、進階病人照護、以及支持在這些領域的優秀教師和工作人員。而優秀的您們,是我們至今仍持續在此領域領先成功的重要因素。在展開新的計畫的同時,我們將支持教師們初步及中期階段的事業的發展,並加強支持與招聘學員;我們也希望資助一些新的教授職位。此外,我們會對某些重要研究項目,特別是在遺傳學和分子生物學和青光眼視網膜疾病上予以撥款,其中也包括啟動基因療法試驗。



This has been a long, hard fight. Throughout the legal battle, however, we have never lost sight of our goal- to cure and prevent blinding disease globally. It is my hope, as I know it is yours, that our advances will benefit eye patients around the world.

我們從不忽視:為治療和防止全球的眼盲疾病,是一個漫長艱苦的要努力奮鬥的目標。這是我的願望,相信也是您的期盼,新計畫的進展將能真正幫助世界各地的眼疾患者。

 

 

 

 

想了解更多有關我們的病人護理計劃、研究或教學計劃,歡迎前往我們的網站或來電詢問。

 

Joan W. Miller, MD

Henry Willard William Professor of Ophthalmology

Chief and Chair of Ophthalmology

Massachusetts Eye and Ear Infirmary

Harvard Medical School

馬薩諸塞州醫院及哈佛醫學院眼耳科醫學會主席Joan

 

 

For more information on our patient care, research or teaching programs, please visit our website at masseyeander.org or call my office.

arrow
arrow
    全站熱搜

    哈佛眼科 發表在 痞客邦 留言(2) 人氣()